Treating BCG-induced disease in children

Area of Science:

• Pediatric Infectious Diseases
• Vaccine-Preventable Diseases
• Clinical Trial Analysis

Background:

• Bacillus Calmette-Guerín (BCG) vaccine prevents tuberculosis but can cause adverse reactions in children.
• Complications range from local to disseminated disease, with higher risks in immunocompromised individuals, including those with HIV.
• Parental distress is common due to BCG-induced manifestations.

Purpose of the Study:

• To evaluate the efficacy of various medical and surgical interventions for treating BCG-induced disease in pediatric patients.
• To assess treatment effects on clinical failure rates and time to illness resolution.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs) identified through comprehensive database searches.
• Inclusion criteria focused on RCTs comparing treatments for BCG-induced disease in children.
• Primary outcomes included therapy failure rates and time to resolution; secondary outcomes were mortality.

Main Results:

• Oral antibiotics (isoniazid, erythromycin, isoniazid/rifampicin) showed uncertain effects on clinical failure.
• Needle aspiration demonstrated potential to reduce persistent BCG lymphadenitis abscesses.
• Local isoniazid instillation alongside aspiration may shorten recovery time for lymphadenitis abscesses.

Conclusions:

• Efficacy of oral antibiotics for BCG-induced disease remains unclear; many non-suppurated lymphadenitis cases resolve spontaneously.
• Needle aspiration and possibly local isoniazid show promise for managing BCG lymphadenitis abscesses.
• Further research is crucial, particularly for HIV-infected infants who face higher risks.